Charles River Laboratories | CRL - Equity Capital And Reserves


Charles River Laboratories reported $2.9B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Agilent USD 7.12B 214M Mar/2026
Align Technology USD 4.15B 100.27M Mar/2026
Bio-Rad Laboratories USD 6.85B 602.3M Mar/2026
Bruker USD 2.46B 35.9M Dec/2025
Cardinal Health USD -2.83B 52M Mar/2026
Charles River Laboratories USD 2.9B 265.94M Mar/2026
Cigna USD 42.21B 497M Mar/2026
Concord Medical Services Hldg CNY -2.24B 362.55M Jun/2025
CVS Health USD 77.46B 2.24B Mar/2026
Danaher USD 52.58B 368M Jun/2026
Dentsply International USD 1.32B 21M Mar/2026
Elevance Health USD 44.88B 981M Jun/2026
Humana USD 18.58B 923M Mar/2026
Illumina USD 2.68B 47M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Intrexon USD 43.17M 75.33M Jun/2024
IQVIA Holdings USD 6.22B 282M Mar/2026
Laboratory Of America USD 8.73B 108.8M Mar/2026
Lakefront Biotherapeutics EUR 3.25B 17.5M Mar/2026
Lonza CHF 9.13B 513M Dec/2025
McKesson USD -2.17B 874M Mar/2026
Merck EUR 29.74B 1.15B Mar/2026
Mettler Toledo International USD -41.88M 18.25M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Quest Diagnostics USD 7.52B 150M Jun/2026
Revvity USD 7.25B 125.54M Dec/2025
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026
UnitedHealth USD 105.32B 3.62B Mar/2026
Veradigm USD 1.02B 159.52M Dec/2022
Waters USD 2.56B 230.55M Dec/2025
West Pharmaceutical Services USD 2.99B 200K Jun/2026